Marc Lang

Marc has a Ph.D. in Chemistry and more than 30 years of experience in medicinal chemistry in the pharmaceutical industry at Novartis. During his career, he contributed personally to three compounds currently on the market: Femara® (aromatase inhibitor); Reyataz® (HIV-protease inhibitor); Tasigna® (Bcr/Abl kinase inhibitor) and several promising compounds still in clinical trials. He currently is a scientific advisor to several pharmaceutical companies.